Hematologic Malignancy
Conditions
Keywords
allo-hct, microbiome, gut engraftment
Brief summary
This is a Phase 2a, open-label, multicenter study to evaluate the safety and efficacy of HMO (PBCLN-010) and B. infantis (PBCLN-014) on the gut microbiome and GI domination by pathobionts in participants receiving allo-HCT. Approximately 60 participants will be enrolled in this study, and all participants will undergo screening assessments up to 28 days before the first study drug dose (D 7). Participants meeting all the eligibility criteria based on the screening assessments will be enrolled and randomly assigned to 1 of the 3 cohorts: * Cohort A (HMO 9.0 g and B. infantis) BID * Cohort B (HMO 4.5 g and B. infantis) BID * Cohort C (Control Cohort): Participants in this cohort will not receive any study drug.
Interventions
DRUGB. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)
PBCLN-010: Human Milk Oligosaccharides (HMO). PBCLN-014: B. infantis.
Sponsors
Prolacta Bioscience
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
Unblinded
Intervention model description
3 cohorts: Cohort A and B receive combination study drug in difference doses (Cohort A receives HMO 9.0 g and B. infantis; Cohort B received HMO 4.5 g and B. infantis) Cohort C does not receive study drug
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent prior to initiation of any study-specific procedure or treatment. 2. Male and female participants 18 to 75 years of age at the time of informed consent. 3. Planning to receive a first allo-HCT. 4. Able to comply with protocol requirements.
Exclusion criteria
1. Participants with prior bowel resection resulting in colostomy 2. Serious medical or psychiatric illness likely to interfere with participation in study. 3. History or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide informed consent or comply with study instructions. 4. Female participants who are pregnant, breastfeeding, lactating, or planning to become pregnant during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of safety and tolerability measures assessed through adverse events, serious adverse events, and adverse events of special interest per treatment group | before treatment, during treatment, or ≤ 56 days after cessation of treatment |
| Rate of gut engraftment of B. infantis through Day 180 among recipients of PBCLN-010 in combination with PBCLN-014 compared with standard of care (SOC) (control cohort). | Through study completion,180 days |
| Duration of gut engraftment of B. infantis through Day 180 among recipients of PBCLN-010 in combination with PBCLN-014 compared with standard of care (SOC) (control cohort). | Through study completion,180 days |
Secondary
| Measure | Time frame |
|---|---|
| Measures of safety and tolerability by physical examinations examined by cohort to assess the effect of oral administration of PBCLN-010 in combination with PBCLN-014 | Dosing period, 43 days |
| Measuring cases of acute graft versus host disease (aGvHD) to determine the cumulative incidence or rate of acute graft versus host disease (aGvHD) at D180 | Through study completion,180 days |
| Measuring the incidence of bloodstream infections, use of anti-infective agents, frequency/length of hospitalizations stays to evaluate the incidence of the infection and other safety events among recipients of study drug compared with SOC | Through study completion,180 days |
| Measuring temperature ≥ 38.0°C (100.4°F) sustained over a 1-hour period concurrent with ANC < 500 cells/mm3 to determine the incidence and duration of febrile neutropenia | Day -7 through neutrophil engraftment |
Countries
United States
Outcome results
None listed